Metabolic Syndrome Rather Than Body Mass Index Is Associated With Treatment Response to Ketamine Infusions
The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Purpose There is a practical need for the identification of pretreatment clinical and epidemiological response predictors to repeat ketamine infusions. Response predictors can serve to guide clinical inclusion of patients and weigh risks versus benefits for those receiving maintenance ketamine. Previous studies indicate a link between obesity, depression, and treatment response. We sought to investigate if body mass index (BMI) or metabolic syndrome could predict treatment response to ketamine. Methods Patients aged 18 to 72 years who were electroconvulsive therapy nonresponders were given a subanesthetic ketamine hydrochloride dose of 0.5 mg/kg delivered intravenously for 40 minutes for an acute series of 3 to 6 infusions every other day. If patients reported at least a 50% decrease in depression symptoms after the acute series, they were moved to a maintenance series of infusions, on an individualized basis. To assess if BMI or metabolic syndrome could predict response, logistic regression models were run to analyze initial responders, sustained responders, and nonresponders. Models were adjusted for age, sex, and baseline depression severity. Results Of the 150 patients analyzed, 56 did not respond to the acute phase, 38 initially responded to the acute phase but relapsed during the maintenance phase, and 56 sustained their response for 1 year. In unadjusted models, BMI was not shown to be a predictor of initial or sustained response. Alternatively, metabolic syndrome defi…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Elevated body mass index (BMI) has been found to be a predictor of response to ketamine,196 but in another study197 elevated BMI was not correlated with ketamine response, and presence of metabolic syndrome was negatively correlated with ketamine response.”
From Ketamine as an antidepressant: Overview of its mechanisms of action and potential predictive biomarkers (2020) · cites this paper as [197]
Citations
Cites
Overweight, Obesity, and Depression: A Systematic Review and Meta-analysis of Longitudinal Studies
Luppino, F. S., de Wit, L. M., Bouvy, P. F., Stijnen, T., Cuijpers, P., Penninx, B. W. J. H., & Zitman, F. G. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.2 · Cited by 4,322 · cited 1×
“”(13) A meta-analysis of longitudinal studies confirmed that obesity and depression are correlated in a bidirectional manner.(14,15) In a study of women only, the risk was bidirectional but stronger in the direction of depression leading to obesity.”
BackgroundUpstream and downstream of mTOR
Hay, N., & Sonenberg, N. (2004) · Genes & Development · doi:10.1101/gad.1212704 · Cited by 4,181 · cited 1×
“The hypothesized mechanisms of ketamine's effect are numerous, and the potential for deleterious effect over time is unknown.(11,12) Thus, identification of pretreatment response predictors of the antidepressant efficacy of repeated ketamine therapy is essential to guide selection of patients and help refine the risk/…”
BackgroundSo depression is an inflammatory disease, but where does the inflammation come from?
Berk, M., Williams, L. J., Jacka, F. N., O’Neil, A., Pasco, J. A., Moylan, S., Allen, N. B., Stuart, A. L., Hayley, A. C., Byrne, M. L., et al. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-200 · Cited by 1,423
Mechanisms of ketamine action as an antidepressant
Zanos, P., & Gould, T. D. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.255 · Cited by 1,127
A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders
Sanacora, G., Frye, M. A., McDonald, W., Mathew, S. J., Turner, M. S., Schatzberg, A. F., Summergrad, P., Nemeroff, C. B., & for the American Psychiatric Association (APA) Council of Research Task Force on Novel Biomarkers and Treatments (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.0080 · Cited by 576
Side-effects associated with ketamine use in depression: a systematic review
Short, B., Fong, J., Galvez, V., Shelker, W., & Loo, C. K. (2018) · The Lancet Psychiatry · doi:10.1016/s2215-0366(17)30272-9 · Cited by 558
Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism
Williams, N. R., Heifets, B. D., Blasey, C., Sudheimer, K., Pannu, J., Pankow, H., Hawkins, J., Birnbaum, J., Lyons, D. M., Rodriguez, C. I., et al. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.18020138 · Cited by 519
Ketamine: A Paradigm Shift for Depression Research and Treatment
Krystal, J. H., Abdallah, C. G., Sanacora, G., Charney, D. S., & Duman, R. S. (2019) · Neuron · doi:10.1016/j.neuron.2019.02.005 · Cited by 455 · cited 1×
“T he discovery of robust antidepressant effects of single or repeated intravenous doses of ketamine,(1) especially in treatment-resistant depression, has led to a “paradigm shift” in depression research and treatment.(2) A thorough evaluation, including severity of mood, suicidality, longitudinal history of mood episo…”
BackgroundPhillips, J. L., Norris, S., Talbot, J., Birmingham, M., Hatchard, T., Ortiz, A., Owoeye, O., Batten, L. A., & Blier, P. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.18070834 · Cited by 418 · cited 1×
“Copyright © 2019 Wolters Kluwer mostly mild and transient adverse effects,(4) but the consequences of long-term “maintenance” ketamine infusions are only recently being reported.(5,6) There is appropriate concern that the unregulated use of ketamine has exceeded the evidence.”
BackgroundObesity effects on depression: systematic review of epidemiological studies
Atlantis, E., & Baker, M. (2008) · International Journal of Obesity · doi:10.1038/ijo.2008.54 · Cited by 399
Cited by
Matveychuk, D., Thomas, R. K., Swainson, J., Khullar, A., MacKay, M.-A., Baker, G. B., & Dursun, S. M. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320916657 · Cited by 209
Smith-Apeldoorn, S. Y., Veraart, J. K., Spijker, J., Kamphuis, J., & Schoevers, R. A. (2022) · The Lancet Psychiatry · doi:10.1016/s2215-0366(22)00317-0 · Cited by 169
Personalized use of ketamine and esketamine for treatment-resistant depression
Medeiros, G. C., Demo, I., Goes, F. S., Zarate, C. A., & Gould, T. D. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03180-8 · Cited by 51
“However, there have been mixed results with negative studies for each of these variables: body mass index [78, 82, 83, 92 – 96], childhood trauma [68, 87], personal history of AUD [12, 78, 87, 93], anhedonia scores [84], anxious features [78 – 80], and non-melancholic depression [97, 98].”
Li, Q., Wang, S., & Mei, X. (2022) · Psychiatry Research · doi:10.1016/j.psychres.2022.114396 · Cited by 38
Iro, C. M., Hamati, R., Mansari, M. E., & Blier, P. (2021) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyab010 · Cited by 31
“Finally, the response to several infusions can be sustained by decreasing the frequency of administration over time (Phillips et al., 2019; Dale et al., 2020).”
Background
Metadata
- Authors
- Dale, R. M., Bryant, K. A., & Thompson, N. R.
- Affiliations
- Cleveland Clinic (US)
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2019-12-11
- Volume
- 40
- Issue
- 1
- Pages
- 75-79
- ISSN
- 0271-0749 (ISSN-L)
- 1533-712X
- OpenAlex
- W2996714229
- Cited by
- 29
- References
- 40
- Citations by year
- 2026: 3 · 2025: 7 · 2024: 4 · 2023: 1 · 2022: 5 · 2021: 4 · 2020: 5
- FWCI
- 2.17
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Health Sciences › Medicine › Physiology (medical) › Diet and metabolism studies
- Keywords
- ketamine, metabolic syndrome, body mass index, obesity, depression, treatment response prediction, hypertension, hyperlipidemia, hyperglycemia, relapse
- MeSH terms
- Adolescent, Adult, Affect, Aged, Antidepressive Agents, Drug Administration Schedule, Female, Humans, Infusions, Intravenous, Ketamine, Male, Middle Aged, Obesity, Registries, Time Factors, Body Mass Index, Treatment Outcome, Metabolic Syndrome, Young Adult, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Metabolic Syndrome Rather Than Body Mass Index Is Associated With Treatment Response to Ketamine Infusions. https://app.cochat.ai/papers/10.1097/jcp.0000000000001149
- The paper
- Dale, R. M., Bryant, K. A., & Thompson, N. R. (2020). Metabolic Syndrome Rather Than Body Mass Index Is Associated With Treatment Response to Ketamine Infusions. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/jcp.0000000000001149
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.